Tesamorelin
Also known as: Egrifta
FDA-approved GHRH analog for HIV-associated lipodystrophy; used off-label for fat loss.
- Typical dose
- 1.4 mg – 2 mg
- Frequency
- once daily
- Route
- Subcutaneous
- Half-life
- 30 minutes
- Routes
- Subcutaneous
- Status
- FDA-approved (HIV lipodystrophy)
Benefits
- Visceral fat reduction
- GH elevation
- Cognitive improvement
Dosing
A common research range for Tesamorelin is 1.4 mg to 2 mg once daily. EGRIFTA SV: 1.4mg/day; original formulation 2mg/day. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Reconstitution
A typical reconstitution for Tesamorelin is 2 mg of peptide in 2 mL of bacteriostatic water, giving roughly 1 mg per mL. Vial's built-in calculator works out the exact syringe draw for any vial size and dose.
Half-life
Tesamorelin has an approximate half-life of 30 minutes. Vial plots the real concentration curve from your logged doses so you can see peak windows and when levels taper.
Storage
2-8°C post-reconstitution.
Reported side effects
- Injection site reactions
- Joint pain
- Peripheral edema
Contraindications
- Active malignancy
- Pregnancy
Track Tesamorelin with Vial
Vial logs every Tesamorelin dose, plots its half-life curve, calculates reconstitution math, and keeps your whole protocol on schedule — on-device and private. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Tesamorelin is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.